Literature DB >> 342229

Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea.

R C Heel, R N Brogden, T M Speight, G S Avery.   

Abstract

Loperamide, a butyramide derivative is a new agent for use in symptomatic control of acute non-specific diarrhoea and chronic diarrhoea. Unlike diphenoxylate or codeine, loperamide does not appear to exert opiate activity in man at normal therapeutic doses. In acute diarrhoea, loperamide provides more rapid control of symptoms than diphenoxylate when given in a flexible dosage according to unformed bowel movements, and in single dose studies 4mg loperamide has a much longer duration of effect than 5mg diphenoxylate. Loperamide is probably superior to diphenoxylate in providing symptomatic control of chronic diarrhoea such as that associated with chronic inflammatory bowel disease or following gastrointestinal surgery. It has been used for up to 3 years in such conditions without evidence of tolerance. The possibility of once daily dosage of loperamide in chronic diarrhoea is an advantage. Side-effects have not proved a problem.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 342229     DOI: 10.2165/00003495-197815010-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  33 in total

1.  Letter: Loperamide in treatment of persistent diarrhoea in children.

Authors:  J P Buts; B F Petit; R de Meyer
Journal:  Br Med J       Date:  1975-09-27

2.  Radioimmunoassay of the antidiarrhoeal loperamide.

Authors:  M Michiels; R Hendriks; J Heykants
Journal:  Life Sci       Date:  1977-08-01       Impact factor: 5.037

3.  [R 18553 in the treatment of acute diarrhea in young children].

Authors:  J M Dubru; A Lambrechts
Journal:  Rev Med Liege       Date:  1974-10-01

4.  Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 4: studies on subacute and chronic toxicity and the effect on reproductive processes in rats, dogs and rabbits.

Authors:  R Marsboom; V Hérin; A Verstraeten; R Vandesteene; J Fransen
Journal:  Arzneimittelforschung       Date:  1974-10

5.  Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 1: in vivo oral pharmacology and acute toxicity. Comparison with morphine, codeine, diphenoxylate and difenoxine.

Authors:  C J Niemegeers; F M Lenaerts; P A Janssen
Journal:  Arzneimittelforschung       Date:  1974-10

6.  Loperamide: an open multicentre trial and double-blind cross-over comparison with placebo in patients with chronic diarrhoea.

Authors:  L Demeulenaere; S Verbeke; M Muls; A Reyntjens
Journal:  Curr Ther Res Clin Exp       Date:  1974-01

7.  Loperamide antagonism of castor oil-induced diarrhea in rats: a quantitative study.

Authors:  F Awouters; C J Niemegeers; J Kuyps; P A Janssen
Journal:  Arch Int Pharmacodyn Ther       Date:  1975-09

8.  Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 5: the pharmacokinetics of loperamide in rats and man.

Authors:  J Heykants; M Michiels; A Knaeps; J Brugmans
Journal:  Arzneimittelforschung       Date:  1974-10

9.  The effect of loperamide on prostaglandin induced diarrhoea in rat and man.

Authors:  S M Karim; P G Adaikan
Journal:  Prostaglandins       Date:  1977-02

10.  Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 6: Clinical pharmacology. Placebo-controlled comparison of the constipating activity and safety of loperamide, diphenoxylate and codeine in normal volunteers.

Authors:  V Schuermans; R Van Lommel; J Dom; J Brugmans
Journal:  Arzneimittelforschung       Date:  1974-10
View more
  28 in total

1.  Effects of the prodrug loperamide oxide, loperamide, and placebo on jejunal motor activity.

Authors:  G Stacher; H Steinringer; C Schneider; G V Vacariu-Granser; F Castiglione; G Gaupmann; U Weber; G Stacher-Janotta
Journal:  Dig Dis Sci       Date:  1992-02       Impact factor: 3.199

2.  Successful management of chronic high-output ileostomy with high dose loperamide.

Authors:  Alicia Mackowski; Han-Kuang Chen; Michael Levitt
Journal:  BMJ Case Rep       Date:  2015-04-22

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 4.  Pathogen-induced secretory diarrhea and its prevention.

Authors:  S Anand; S Mandal; P Patil; S K Tomar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-29       Impact factor: 3.267

5.  The effects of loperamide on continence problems and anorectal function in obese subjects taking orlistat.

Authors:  Mark Fox; Bernadette Stutz; Dieter Menne; Michael Fried; Werner Schwizer; Miriam Thumshirn
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

6.  Inhibition by loperamide of deoxycholic acid induced intestinal secretion.

Authors:  U M Farack; K Loeschke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-03       Impact factor: 3.000

7.  Effect of increasing oral doses of loperamide on gallbladder motility in man.

Authors:  W P Hopman; G Rosenbusch; J B Jansen; C B Lamers
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

8.  Effect of loperamide and delay of bowel motility on bile acid malabsorption caused by late radiation damage and ileal resection.

Authors:  R Valdés Olmos; F den Hartog Jager; C Hoefnagel; B Taal
Journal:  Eur J Nucl Med       Date:  1991

9.  Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats.

Authors:  Iman A Elkiweri; Yan Ling Zhang; Uwe Christians; Ka-Yun Ng; Martha C Tissot van Patot; Thomas K Henthorn
Journal:  Anesth Analg       Date:  2009-01       Impact factor: 5.108

Review 10.  Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.

Authors:  Chun Seng Lee; Elizabeth J Ryan; Glen A Doherty
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.